Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
- 560 Downloads
Ipilimumab is a fully human, monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune checkpoint molecule that negatively regulates T-cell activation . It is hypothesized that CTLA-4 blockade can break peripheral tolerance to tumor antigens, promoting an antitumor immune response . Ipilimumab has shown durable objective responses and encouraging long-term survival in phase II trials involving patients with metastatic melanoma [3, 4, 5, 6]. In a phase III, randomized controlled trial, ipilimumab monotherapy demonstrated a statistically significant improvement in overall survival in previously treated patients with metastatic melanoma . Recently, the results of another phase III trial with ipilimumab were reported for previously untreated patients with metastatic melanoma, which showed a statistically significant improvement in overall survival for ipilimumab plus dacarbazine compared with dacarbazine alone . The treatment-related...
KeywordsIpilimumab Drug-induced hepatitis CTLA-4 Immunosuppressive therapy Metastatic melanoma
Cytotoxic T-lymphocyte antigen-4
Upper limit of normal
Editorial and writing assistance was provided by StemScientific, funded by Bristol-Myers Squibb Co. This research was supported in part by the Intramural Research Program of the US National Institutes of Health (National Cancer Institute).
Conflict of interest
David E. Kleiner: No financial, professional or personal conflicts of interest exist with respect to this work. David Berman is an employee of Bristol-Myers Squibb Company and discloses ownership of equity in the company.
- 3.Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591–5598.PubMedCrossRefGoogle Scholar
- 6.Maio M, Lebbé C, Neyns B, et al. Three-Year Survival Rates for Patients with Advanced Melanoma Who Received Ipilimumab at 10 mg/kg in Phase II Trials [Abstract]. In: Presented at the XIV annual meeting of the perspectives in melanoma, 2010 September 17–18, Amsterdam, The Netherlands. 2010.Google Scholar